Brainstorm Cell Therapeutics Inc Capital Reinvestment Ratio

Latest as of June 2018: 3.91x

Brainstorm Cell Therapeutics Inc capital reinvestment ratio. Brainstorm Cell Therapeutics Inc (BCLI) has a Capital Reinvestment Ratio of 3.91x as of June 2018, meaning it reinvests 4% of its operating cash flow ($55.00K) in capital expenditures ($215.00K). Check BCLI total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.

Capital Reinvestment Ratio

3.91x

Capex / Operating Cash Flow

Operating Cash Flow

$55.00K

USD

Capital Expenditures

$215.00K

USD

Data as of

Jun 2018

Most recent filing

Brainstorm Cell Therapeutics Inc Capital Reinvestment Ratio by Year (None–None)

Brainstorm Cell Therapeutics Inc capital reinvestment ratio by year from None to None. For the full cash flow conversion analysis, see cash flow conversion of Brainstorm Cell Therapeutics Inc.

Year	Reinvestment Ratio	Operating CF (USD)	Capital Expenditures	YoY Change

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow